A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Key Inclusion Criteria: * Male of age 18-50 years * Clinical Diagnosis of Androgenetic Alopecia * Written informed consent Key Exclusion Criteria: * Other types of Alopecia or other diseases that can cause hair loss * Clinically significant scalp disease such as seborrheic dermatitis or psoriasis * Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator * Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose